Concert Pharmaceuticals Inc

Concert Pharmaceuticals — Investor Presentation (August 2022)

22 slides from Concert Pharmaceuticals's investor presentation, Aug 4, 2022

  1. Slide 1: Creating New Possibilities for Patients to Live Their Lives

    Creating New Possibilities for Patients to Live Their Lives August 2022 © 2022 Concert Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Any statements in this presentation about our future expectations, plans and prospects, including, among others, statements about our expectations regarding the development of CTP-543, the potential for CTP-543 to be a best-in-class treatment for the treatment of alopecia

  3. Slide 3: CoNCERT: Creating New Opportunities in Dermatology

    CoNCERT: Creating New Opportunities in Dermatology 3 Developing small molecules for autoimmune dermatology Late-stage, patient-centric, clinical company Successfully out-licensed multiple candidates Cash into second quarter of 2023 • Successfully completed two pivotal trials to support NDA submissio

  4. Slide 4: Late-Stage Clinical Program and Strategic Value Creation

    Late-Stage Clinical Program and Strategic Value Creation 4 Phase 1 Phase 2 Phase 3 Anticipated Milestones Ownership CTP-543 Deuruxolitinib Alopecia Areata NDA submission planned 1H 2023 AVP-786 Deudextromethorphan hydrobromide and quinidine sulfate Alzheimer’s Agitation Schizophrenia Negative Sympto

  5. Slide 5: CTP-543: Compelling Opportunity for Alopecia Areata

    CTP-543: Compelling Opportunity for Alopecia Areata 5 • Serious autoimmune disorder with significant unmet patient need • CTP-543 has Breakthrough Therapy designation Large Market Opportunity • Plan to file NDA in 1H 2023 • Pre-commercial initiatives underway Preparing for Commercialization • Orange

  6. Slide 6: Alopecia Areata: A Devastating Autoimmune Disease

    Alopecia Areata: A Devasting Autoimmune Disease 6 Limited Treatment Options Available • Strong patient advocacy • FDA PFDDI meeting held September 2017 • CTP-543 potentially best- in-class ‒ Breakthrough Therapy designation granted by FDA Common Disorder 1 Est. 700,000-1,600,000 patients: Benigno M.

  7. Slide 7: THRIVE-AA Studies Achieve Primary Endpoint: Both Doses Highly Statistically Different From Placebo

    THRIVE-AA Studies Achieve Primary Endpoint: Both Doses Highly Statistically Different From Placebo • Randomized >1,200 adult patients with moderate to severe alopecia areata across two double- blind, randomized, placebo-controlled Phase 3 trials ‒ Inclusion criteria: at least 50% hair loss as measur

  8. Slide 8: THRIVE-AA1 Primary Endpoint: Patients Achieving Absolute SALT Score ≤20 at Week 24

    THRIVE-AA1 Primary Endpoint: Patients Achieving Absolute SALT Score ≤20 at Week 24 8 0 10 20 30 40 50 60 8 mg BID 12 mg BID 42% 1% Placebo ***** 30%***** ***** p<0.0001 vs PBO THRIVE-AA1: CTP-543 Phase 3 Results n= 140 n= 351 n= 215 Pe rc en t o f P at ie nt s

  9. Slide 9: THRIVE-AA2 Primary Endpoint: Patients Achieving Absolute SALT Score ≤20 at Week 24

    0 10 20 30 40 50 60 8 mg BID 12 mg BID 38% 1% Placebo 33% 60 % THRIVE-AA2 Primary Endpoint: Patients Achieving Absolute SALT Score ≤20 at Week 24 9***** p<0.0001 vs PBO THRIVE-AA2: CTP-543 Phase 3 Results ***** ***** n= 127 n= 249 n= 127 Pe rc en t o f P at ie nt s

  10. Slide 10: THRIVE-AA1: Statistically Significant Differences from Placebo of Hair Regrowth as Early as Eight Weeks

    THRIVE-AA1: Statistically Significant Differences from Placebo of Hair Regrowth as Early as Eight Weeks 10 THRIVE-AA1 Key Secondary Endpoint: Patients Achieving Absolute SALT Score ≤20 by Weeks on Treatment 0 10 20 30 40 50 60 Week 8 Week 12 Week 16 Week 20 Week 24 Pe rc en t o f P at ie nt s Placeb

  11. Slide 11: THRIVE-AA2: Statistically Significant Differences from Placebo of Hair Regrowth as Early as Twelve Weeks

    0 10 20 30 40 50 60 Week 8 Week 12 Week 16 Week 20 Week 24 Pe rc en t o f P at ie nt s Placebo 8 mg BID 12 mg BID ***** THRIVE-AA2: Statistically Significant Differences from Placebo of Hair Regrowth as Early as Twelve Weeks 11 THRIVE-AA2 Key Secondary Endpoint: Patients Achieving Absolute SALT Scor

  12. Slide 12: THRIVE-AA1: Statistically Significant Differences in Relative Change in SALT from Baseline

    THRIVE-AA1: Statistically Significant Differences in Relative Change in SALT from Baseline as Early as 4 Weeks 12 0 10 20 30 40 50 60 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 M ea n % R el at iv e C ha ng e in S AL T Sc or e Placebo 8 mg BID 12 mg BID ***** ***** 2% 41% 50% ***** p<0.0001 vs PB

  13. Slide 13: THRIVE-AA2: Statistically Significant Differences in Relative Change in SALT from Baseline

    THRIVE-AA2: Statistically Significant Differences in Relative Change in SALT from Baseline as Early as 4 Weeks 13 -10 0 10 20 30 40 50 60 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 M ea n % R el at iv e C ha ng e in S AL T Sc or e Placebo 8 mg BID 12 mg BID ***** ***** - 2% ***** p<0.0001 vs PBO

  14. Slide 14: THRIVE-AA1: Highly Statistically Significant Differences vs Placebo in Patient Satisfaction at Week 24

    THRIVE-AA1: Highly Statistically Significant Differences vs Placebo in Patient Satisfaction at Week 24 14 THRIVE-AA1: Key Secondary Endpoint: Satisfaction of Hair Patient Reported Outcome (SPRO) Responders at Week 24 ***** p<0.0001 vs PBO 0 10 20 30 40 50 60 8 mg BID 12 mg BIDPlacebo Pe rc en ta ge

  15. Slide 15: THRIVE-AA2: Highly Statistically Significant Differences vs Placebo in Patient Satisfaction at Week 24

    THRIVE-AA2: Highly Statistically Significant Differences vs Placebo in Patient Satisfaction at Week 24 15 THRIVE-AA2 Key Secondary Endpoint: Satisfaction of Hair Patient Reported Outcome (SPRO) Responders at Week 24 Responder is defined as patient response of ‘very satisfied’ or ‘satisfied’ 0 10 20

  16. Slide 16: THRIVE-AA1: Favorable Safety/Tolerability Profile

    THRIVE-AA1: Favorable Safety/Tolerability Profile • CTP-543 treatment was generally well tolerated • 9 patients reported SAEs: placebo (4), 8 mg twice-daily (4) and 12 mg twice-daily (1) ‒ Only 1 patient (8 mg) reported SAEs (2) assessed as possibly related to treatment • No pulmonary embolisms or d

  17. Slide 17: THRIVE-AA2: Favorable Safety/Tolerability Profile

    THRIVE-AA2: Favorable Safety/Tolerability Profile • CTP-543 treatment was generally well tolerated • 5 patients reported SAEs: 8 mg twice-daily (3) and 12 mg twice-daily (2) ‒ Only 1 patient (8 mg) reported an SAE assessed as possibly related to treatment • No pulmonary embolisms or deep vein thromb

  18. Slide 18: CTP-543: Potential Best-in-Class Treatment in Alopecia Areata

    CTP-543: Potential Best-in-Class Treatment in Alopecia Areata Conclusions from the THRIVE-AA Phase 3 program*:  Primary endpoint achieved: significant scalp regrowth at 24 weeks  Early onset of effect: significant differences as early as 8 to 12 weeks and maintained throughout study  Patient sati

  19. Slide 19: CTP-543 for Alopecia Areata: Pre-Commercial Planning

    CTP-543 for Alopecia Areata: Pre-Commercial Planning • CTP-543 has highly competitive profile based on Phase 3 results • Alopecia areata represents potential blockbuster opportunity • High unmet need with strong patient advocacy and demand • Multiple pre-commercial initiatives underway ‒ Payor evide

  20. Slide 20: CTP-543: Compelling Opportunity for Alopecia Areata

    CTP-543: Compelling Opportunity for Alopecia Areata 20 • Serious autoimmune disorder with significant unmet patient need • CTP-543 has Breakthrough Therapy designation Large Market Opportunity • Plan to file NDA in 1H 2023 • Pre-commercial initiatives underway Preparing for Commercialization • Orang

  21. Slide 21: Financial Position and Milestones

    Financial Position Clinical Milestones Regulatory Milestones 21 Financial Position and Milestones  Successful THRIVE-AA1 Phase 3 trial topline results reported Q2 2022  Successful THRIVE-AA2 Phase 3 trial topline results reported Q3 2022 • Cash, cash equivalents and investments: $153.7M as of June

  22. Slide 22: For additional information contact

    © 2022 Concert Pharmaceuticals, Inc. All Rights Reserved. NASDAQ: CNCE www.concertpharma.com @ConcertPharma For additional information contact: Justine Koenigsberg ir@concertpharma.com

Concert Pharmaceuticals — Investor Presentation (August 2022) on 6ix